DK2124638T3 - Sammensætning, der er præstationforøgende, samt anvendelse af den - Google Patents

Sammensætning, der er præstationforøgende, samt anvendelse af den Download PDF

Info

Publication number
DK2124638T3
DK2124638T3 DK08712839.3T DK08712839T DK2124638T3 DK 2124638 T3 DK2124638 T3 DK 2124638T3 DK 08712839 T DK08712839 T DK 08712839T DK 2124638 T3 DK2124638 T3 DK 2124638T3
Authority
DK
Denmark
Prior art keywords
nitrate
nitrite
vol
combination
inorganic
Prior art date
Application number
DK08712839.3T
Other languages
English (en)
Inventor
Jon Lundberg
Eddie Weitzberg
Original Assignee
Heartbeet Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39721497&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2124638(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Heartbeet Ltd filed Critical Heartbeet Ltd
Application granted granted Critical
Publication of DK2124638T3 publication Critical patent/DK2124638T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52Adding ingredients
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/21Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01DCOMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
    • C01D9/00Nitrates of sodium, potassium or alkali metals in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (9)

1. Fremgangsmåde til ikke-terapeutisk forøgelse af et pattedyrs præstation, hvor den forøgede præstation ved fysisk udøvelse ytrer sig ved reduceret oxygenforbrug (VO2), kendetegnet ved, at uorganisk nitrat, nitrit eller en kombination deraf indgives oralt, hvor dosen af nitrat andrager 0,01 - 10 mmol natriumnitrat/kg le-gemsvægt/dag, dosen af nitrit andrager 0,001 - 1 mmol/kg legemsvægt/dag, og hvor doseforholdsintervallet, når nitrat og nitrit indgives i kombination, andrager 5:1 til 100:1 (nitratmitrit), og hvor den nævnte præstation er forøget i sammenligning med pattedyrets fysiske præstation ved fravær af indgivelse af uorganisk nitrat og/eller nitrit.
2. Fremgangsmåde ifølge krav 1, hvor nitrat og/eller nitrit indgives sammen med polyphenoler.
3. Anvendelse af uorganisk nitrat eller nitrit eller en kombination deraf til ikke-terapeutisk forøgelse af et pattedyrs præstation, hvor den forøgede præstation under fysisk udøvelse ytrer sig ved formindsket oxygenforbrug (VO2), kendetegnet ved, at uorganisk nitrat, nitrit eller en kombination deraf indgives oralt, hvor dosen af nitrat andrager 0,01 - 10 mmol natriumnitrat/kg legemsvægt/dag, dosen af nitrit andrager 0,001 - 1 mmol/kg legemsvægt/dag, og hvor doseforholdsintervallet, når nitrat og nitrit indgives i kombination, andrager 5:1 til 100:1 (nitratmitrit), og hvor den nævnte præstation er forøget i sammenligning med pattedyrets fysiske præstation ved fravær af indgivelse af uorganisk nitrat og/eller nitrit.
4. Anvendelse ifølge krav 3, hvor sammensætningen foreligger i form af en væske, en pasta, en stang (barre), en kage, et pulver, et granulat, en brusetablet, en tablet, en kapsel, en pastil, en tyggegummi, en hurtig smeltende smelte-tablet eller -wafer, en sugetablet eller en spray.
5. Anvendelse ifølge krav 3 eller 4, hvor sammensætningen foreligger i form af en sportsdrik, en energidrik, en sportsstang eller -barre eller en energi-stang eller -barre.
6. Anvendelse ifølge krav 3, 4 eller 5, hvor kilden til uorganisk nitrat er udvalgt blandt et koncentrat, en ekstrakt eller en juice af nitrat-holdige grøntsager eller en uorganisk nitratsalt.
7. Anvendelse ifølge krav 3, 4, 5 eller 6, hvor den uorganiske nitrat er anvendt i kombination med polyphenoler.
8. Anvendelse ifølge krav 3, 4, 5, 6 eller 7, hvor den uorganiske nitrat er anvendt i kombination med levende bakterier, som er i stand til forøgelse af nitrat- eller nitrit-reduktion.
9. Anvendelse ifølge krav 3, 4, 5, 6, 7 eller 8, hvor den uorganiske nitrat er anvendt i kombination med ethanol i en mængde mindre end 5 % (v/v), fortrinsvis mindre end 2 % (v/v), mere foretrukket imellem 0,5 - 1 % (v/v).
DK08712839.3T 2007-02-26 2008-02-26 Sammensætning, der er præstationforøgende, samt anvendelse af den DK2124638T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0700520 2007-02-26
SE0700729 2007-03-22
PCT/SE2008/050211 WO2008105730A1 (en) 2007-02-26 2008-02-26 Performance enhancing composition and use thereof

Publications (1)

Publication Number Publication Date
DK2124638T3 true DK2124638T3 (da) 2017-03-20

Family

ID=39721497

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08712839.3T DK2124638T3 (da) 2007-02-26 2008-02-26 Sammensætning, der er præstationforøgende, samt anvendelse af den

Country Status (12)

Country Link
US (2) US9180140B2 (da)
EP (2) EP3159000A1 (da)
JP (1) JP2010519335A (da)
CA (1) CA2678093C (da)
CY (1) CY1118847T1 (da)
DK (1) DK2124638T3 (da)
ES (1) ES2618655T3 (da)
HR (1) HRP20170355T1 (da)
HU (1) HUE031982T2 (da)
PL (1) PL2124638T3 (da)
PT (1) PT2124638T (da)
WO (1) WO2008105730A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759477B2 (en) 2007-02-26 2023-09-19 Heartbeet Ltd. Compositions of nitrates and methods of use thereof
US10842813B2 (en) 2007-02-26 2020-11-24 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US10835555B2 (en) 2007-02-26 2020-11-17 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US10406118B2 (en) 2007-02-26 2019-09-10 Jon Lundberg Use of nitrites and nitrates and compositions containing these
US10821132B2 (en) 2007-02-26 2020-11-03 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
WO2009065142A2 (en) 2007-11-15 2009-05-22 Biomedical Research Foundation Of Northwest Louisiana Use of nitrite salts in chronic ischemia
WO2010147742A2 (en) 2009-06-18 2010-12-23 Theravasc Inc. Use of nitrite salts in treating tissue damage
DE102009041425B4 (de) * 2009-08-13 2017-08-31 Aeroscan Gmbh Verfahren zur Steuerung eines Spiroergometriesystems und Spiroergometriesystem
ES2633618T3 (es) 2009-10-14 2017-09-22 Theravasc Inc. Formulaciones farmacéuticas de nitrito y sus usos
HUE032165T2 (en) 2011-04-13 2017-09-28 Thermolife Int Llc Methods of using N-actyl-beta-alanine
BR112014003414B1 (pt) * 2011-08-17 2021-09-21 Board Of Regents, The University Of Texas System Composição e sistema de entrega oral para aumento de níveis fisiológicos e terapêuticos de óxido nítrico
EP2675291B1 (en) * 2012-05-07 2015-10-07 Premier Nutrition Corporation Puree compositions having specific carbohydrate ratios and methods for using same
BR112015019802A2 (pt) 2013-02-20 2017-07-18 Theravasc Inc formulações farmacêuticas de nitrito e usos das mesmas
JP6531990B2 (ja) * 2013-02-28 2019-06-19 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 心肺血行動態を改善するための無機亜硝酸塩
WO2014201360A1 (en) * 2013-06-13 2014-12-18 The Hershey Company Food compositions that enhance nitric oxide mediated signalling
US11338005B2 (en) 2013-06-28 2022-05-24 Arjuna Natural Private Limited Medicinal composition of amaranth origin for cardiovascular treatment
AU2014300493B2 (en) 2013-06-28 2020-01-16 Arjuna Natural Private Limited A medicinal composition of Amaranth extract origin having enriched nitrate content and a method of preparing the same
US20160095341A1 (en) * 2014-06-13 2016-04-07 The Hershey Company Food compositions that enhance nitric oxide mediated signalling
JP2016032808A (ja) * 2014-07-30 2016-03-10 株式会社サンダーアーク 機能性飲料水及びその製造方法
BR112017023509B1 (pt) 2015-05-06 2022-08-30 Yara International Asa Ração adequada para uma fêmea de mamífero monogástrico em fase de lactação e/ou gestação
ES2959184T3 (es) 2015-05-27 2024-02-21 Vdf Futureceuticals Inc Composiciones y métodos para aumentar el rendimiento atlético
US11241406B2 (en) 2015-08-28 2022-02-08 Nature's Sunshine Products, Inc. Compositions and methods for acutley raising nitric oxide levels
US10362998B2 (en) 2016-02-25 2019-07-30 Samsung Electronics Co., Ltd. Sensor-based detection of changes in health and ventilation threshold
US10420514B2 (en) 2016-02-25 2019-09-24 Samsung Electronics Co., Ltd. Detection of chronotropic incompetence
US10172517B2 (en) 2016-02-25 2019-01-08 Samsung Electronics Co., Ltd Image-analysis for assessing heart failure
US11164596B2 (en) 2016-02-25 2021-11-02 Samsung Electronics Co., Ltd. Sensor assisted evaluation of health and rehabilitation
US11090342B2 (en) 2016-04-11 2021-08-17 President And Fellows Of Harvard College Probiotic formulations for improving athletic performance
CA3026639A1 (en) 2016-06-06 2017-12-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Uses of inorganic nitrite for increasing nerve conduction velocity
CN110461171A (zh) 2017-03-23 2019-11-15 美生盐有限公司 含甜菜根的组合物
GB202004927D0 (en) 2020-04-03 2020-05-20 Sis Science In Sport Ltd Compositions
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
CN112772789B (zh) * 2020-12-31 2023-05-09 内江师范学院 石榴皮饲料用功能添加剂、制备方法及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB962209A (en) * 1962-04-19 1964-07-01 Upjohn Co Multi-vitamin compositions containing fluorides
US4868179A (en) * 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
EP0511587A1 (en) * 1991-04-26 1992-11-04 Takeda Chemical Industries, Ltd. Slimming composition
US5476847A (en) 1994-06-29 1995-12-19 Schering Corporation Derivatives of phosphinic acid useful as endothelin converting enzyme inhibitors
US20050036996A1 (en) * 1996-12-24 2005-02-17 Edmond Roussel Absorbable composition containing propionic bacteria capable of releasing nitric oxide in the human or animal alimentary canal
DE69737510T2 (de) 1996-12-30 2007-12-06 Battelle Memorial Institute, Columbus Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation
US6117872A (en) * 1998-06-23 2000-09-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
EP1115389B1 (en) 1998-09-25 2014-03-12 PhilERA New Zealand Limited Fructosamine oxidase: antagonists and inhibitors
DE19913437B4 (de) * 1999-03-25 2009-05-14 Karl Müller GmbH & Co. Verwendung einer Umrötungsmischung
US6465463B1 (en) * 1999-09-08 2002-10-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
EP1381582A2 (en) * 2000-11-02 2004-01-21 The Lubrizol Corporation Stabilized energetic water in oil emulsion composition
KR20020057695A (ko) * 2001-01-03 2002-07-12 류경열 야채 종합 비타민 강정제 제조방법
US20030036565A1 (en) * 2001-06-22 2003-02-20 Wisconsin Alumni Research Foundation Cancer chemopreventive agents
SE0203817D0 (sv) 2002-12-20 2002-12-20 Jon Lundberg New composition
KR100492083B1 (ko) * 2003-02-22 2005-06-01 삼성전자주식회사 화상형성장치의 급지 카세트
JP4100224B2 (ja) * 2003-04-07 2008-06-11 大正製薬株式会社 飲料組成物
DE602004008927T2 (de) 2003-07-09 2008-06-05 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen
WO2005097085A1 (en) * 2004-04-08 2005-10-20 Micro Nutrient, Llc Nutrient system for individualized responsive dosing regimens
US20050266018A1 (en) * 2004-05-27 2005-12-01 Boreyko Benson K Nutraceutical compositions with mangosteen
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
WO2006110601A2 (en) * 2005-04-07 2006-10-19 Nitromed, Inc. The genetic risk assessment in heart failure: impact of the genetic variation of nos3
GB0522566D0 (en) 2005-11-04 2005-12-14 Novartis Ag Organic compounds
US10406118B2 (en) * 2007-02-26 2019-09-10 Jon Lundberg Use of nitrites and nitrates and compositions containing these
US8303995B1 (en) * 2008-06-13 2012-11-06 Board Of Regents, The University Of Texas System Nitrite formulations and their use as nitric oxide prodrugs

Also Published As

Publication number Publication date
HUE031982T2 (en) 2017-08-28
EP2124638A1 (en) 2009-12-02
EP2124638A4 (en) 2014-04-02
HRP20170355T1 (hr) 2017-05-19
ES2618655T3 (es) 2017-06-21
PT2124638T (pt) 2017-03-13
JP2010519335A (ja) 2010-06-03
CA2678093C (en) 2017-10-24
EP3159000A1 (en) 2017-04-26
WO2008105730A1 (en) 2008-09-04
CY1118847T1 (el) 2018-01-10
US20150352147A1 (en) 2015-12-10
CA2678093A1 (en) 2008-09-04
EP2124638B1 (en) 2016-12-07
US9180140B2 (en) 2015-11-10
US20100047344A1 (en) 2010-02-25
US10555968B2 (en) 2020-02-11
PL2124638T3 (pl) 2017-07-31

Similar Documents

Publication Publication Date Title
DK2124638T3 (da) Sammensætning, der er præstationforøgende, samt anvendelse af den
AU2008219834B2 (en) New use of nitrites and nitrates and compositions containing these
US11096409B2 (en) Compositions of nitrates and methods of use thereof
US9446006B2 (en) Hydroxytyrosol combinations for enhancing mitochondrial function and energy production
US11723917B2 (en) Compositions of nitrates and methods of use thereof
US10835555B2 (en) Compositions of nitrates and methods of use thereof
WO2017187033A1 (fr) Procédé d'évaluation de la capacité d'une composition à prévenir la fatigue et les dommages musculaires; complément alimentaire et medicament
KR20090117762A (ko) (-)-에피갈로카테킨 갈레이트의 신규한 용도
US11759477B2 (en) Compositions of nitrates and methods of use thereof